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This aerospace medicine clerkship project is under the direction of Dr. Sharmila Watkins and is 
in cooperation with Dr. Eric Kerstman and Dr. Ronak Shah.  
The questions of the research project are: 
1. What are the main drivers of evacuation and loss of crew life (LOCL) on three Design 
Reference Missions (DRMs): Near Earth Asteroid (NEA), Lunar Sortie and Lunar 
Outpost using an inexhaustible International Space Station medical kit  
2. What are the treatment designations for these driving medical conditions as listed in 
Expedition Medical Condition List (EMCL) 
3. Do the drivers make sense in the context of the given Design Reference Mission (DRM) 
4. Do any EMCL treatment designations need re-assessing  
The IMM simulations were run with the help of Millennia Foy. The number of trials run was 
100,000. The outputs fell under four categories, best case (treated and untreated) and worst case 
(treated and untreated). Each of the DRMs were run with an exhaustible ISS resource kit and an 
inexhaustible ISS resource kit. Outputs were Crew Health Index (based on functional impairment 
rates), evacuation and LOCL.  
Only evacuation and LOCL were evaluated for the three DRMs (NEA, Sortie, and Outpost). The 
top 15 medical conditions causing evacuation and LOCL were evaluated. It was hypothesized 
that the top 15 drivers of evacuation and loss of crew life in each Design Reference Mission 
(DRM) would have a “shall” treatment designation in the Expedition Medical Condition List 
(EMCL). 
For evacuation and LOCL, the data was compiled as follows. The raw data was taken from the 
inexhaustible ISS resource scenario and showed conditions as either best or worst case. The 
number of occurrences per 100,000 trials for best and worst case scenarios for each medical 
condition were added together and then arranged from highest to lowest. The top 15 medical 
conditions were then chosen.   
For example, if evacuation due to appendicitis-worst case- occurred 16 times on NEA, 




found and the occurrence number was added to the number of occurrences of worst case. 
This created a total number of evacuations due to appendicitis.  
 
When the data was accumulated in this fashion, it gave the total number of evacuations, or 
LOCL, due to that medical condition.  
In the excel spreadsheet the following was recorded:  
 The medical condition  
 The occurrence rate per 100,000 trials  
 The expedition medical condition list’s treatment designation for that specific 
medical condition for that specific DRM  
o For example, wrist fracture in Lunar Outpost is “should” and for Lunar 
Sortie it is “not addressed”  
o Treatment designations: 2 for shall, 1 for should and 0 for not addressed  
 n missions per event. This provided perspective and relevance to the occurrence 
rate.  This was done by dividing the total number of trials, 100,000 in this case, by 
the occurrence rate.  
 
Also, pie graphs containing the top 15 medical conditions and their occurrence rates were 
provided for evacuation and LOCL for each DRM.  
The reason that only the inexhaustible ISS resource kit was used was because the simulations 
were run with version 3.5 of the IMM. No timeline exists for this version so all medical 
conditions that will occur in the mission occur on the same time point. When medical conditions 
occur simultaneously the condition with the highest incidence is treated first. Thus, when one 
uses an exhaustible medical kit, higher incidence conditions are treated preferentially. In general, 
most of the conditions that have a higher incidence are less severe; therefore one will see a 
skewing of data towards more severe conditions.  It was considered prudent to report using an 
inexhaustible kit because the data would be more realistic.  
In future projects, it would be ideal to examine the drivers of CHI in these DRMs as they may 
give drivers that are wholly different from conditions causing evacuation and LOCL. Also, using 



















































































































Clinical Phase I - Clinical Phase II - Clinical Phase III -
Diagnosis & Initial 
Treatment1
On-going Treatment / 
Convalescence2 Recovered / Mission End State
3
FI* Duration FI* Duration FI* EVAC** LOCL**












100 1.5 32 ‐ 74 48 ‐ 168 0 ‐ 74 100 34 ‐ 100
Untreated 
Best Case N/A N/A 32 ‐ 74 24 ‐ 72 0 ‐ 51 0 ‐ 100 0
Untreated 



























































VIIP 797 2 125
Dental Abscess  780 2 128
Nephrolithiasis  464 2 215
Sepsis 279 2 358
Traumatic hypovolemic shock 240 0 416
Stroke (CVA) 212 1 471
Smoke inhalation/Toxic 
exposure  148 2 675
Wrist fracture  135 1 740
Chest pain/angina  119 1 840
Hip/proximal femur fracture  115 0 869
Back Injury  107 2 934
Atrial fibrillation/Atrial flutter 103 2 970
Appendicitis  92 2 1086
Head injury  72 0 1388



































Sepsis  148 2 675
Traumatic hypovolemic 
shock 101 0 990
Stroke (CVA) 60 1 1666
Medication 
Overdose/adverse reaction  51 2 1960
Sudden cardiac arrest  41 1 2439
Head injury  36 0 2777
Decompression sickness 33 2 3030
Chest injury/pneumothorax  33 1 3030
Smoke inhalation/Toxic 
exposure  30 2 3333
Appendicitis  30 2 3333
Abdominal injury  6 1 16666
Burns secondary to fire 5 2 20000
Choking/obstructed airway 2 2 50000
Cardiogenic shock secondary 
to MI 2 0 50000

































Medical condition  Occurrence rate per 100k trials  EMCL n (1 event per n missions)
Dental Abscess  52 2 1923
Nephrolithiasis  38 2 2631
Decompression sickness 27 2 3703
Sepsis  22 2 4545
Smoke Inhalation /Toxic 
exposure 17 2 5882
Stroke (CVA) 15 0 6666
Head injury  13 0 7692
Wrist fracture  12 0 8333
Traumatic hypovolemic shock 12 0 8333
Hip/proximal femur fracture  9 0 11111
Urinary retention  8 2 12500
Back injury  7 2 14285
Chest pain/angina  5 0 20000
Acute arthritis  4 ‐‐ 25000
























Decompression sickness 16 2 6250
Sepsis  8 2 12500
Head injury 7 0 14285
Stroke (CVA) 7 0 14285
Chest 
injury/pneumothorax 2 0 50000
Medication 
overdose/adverse reaction 2 2 50000
Traumatic hypovolemic 
shock 2 0 50000
Appendicitis  1 2 100000
Radiation syndrome  1 2 100000




































Medical condition  Occurrence rate per 100k trials  EMCL n (1 event per n missions)
VIIP 1028 2 97
Dental abscess  549 2 182
Nephrolithiasis  357 2 280
Decompression sickness 286 2 349
Sepsis 207 2 483
Stroke (CVA) 141 1 709
Traumatic hypovolemic shock 137 0 729
Wrist fracture 106 1 943
Smoke inhalation/toxic exposure  99 2 1010
Hip/proximal femur fracture  98 0 1020
Back injury  80 2 1250
Atrial fibrillation/atrial flutter 79 2 1265
Chest pain/angina  76 1 1315
Appendicitis  76 2 1315


































Decompression sickness 135 2 740
Sepsis 98 2 1020
Traumatic hypovolemic 
shock 52 0 1923
Medication 
overdose/adverse reaction  49 2 2040
Sudden cardiac arrest 32 1 3125
Stroke (CVA) 30 1 3333
Head injury 27 0 3703
Appendicitis  26 2 3846
Smoke inhalation/toxic 
exposure  21 2 4761
Chest injury/pneumothorax 20 1 5000
Abdominal injury  7 0 14285
Choking/obstructed airway 1 2 100000
Seizures  1 2 100000
Burns secondary to fire 1 2 100000
Cardiogenic shock secondary 


































































































































































































































































































































































Abdominal injury** 0 50 100 100
Acute chest pain/angina  50 100 100 100
Chest injury/pneumothorax 0 50 50 100
Head Injury 0 50 100 100
Hip/proximal femur fracture  0 100 100 100
Hypovolemic shock 100 100 100 100
Neurogenic shock** 50 100 100 100
Stroke 50 100 100 100
Sudden Cardiac Death** 100 50 0 0

















Abdominal injury  0 0 67 100
Chest injury/pneumothorax 0 0 59 100
Head injury/TBI 0 0 50 100
Hypovolemic shock 0 50 100 100
Neurogenic Shock 0 50 50 100
Stroke 0 0 50 100

































Medical condition  Number in trial  Occurrence rate per 100k trials  Probability of EVAC 
Herpes Zoster Reactivation 
(Shingles) (untreated) 1 1700 100
Urinary Tract Infection (untreated) 2 1260 50
Otitis media (untreated) 3 1089 50
Gastroenteritis (untreated) 4 1013 50
Sinusitis (untreated) 5 812 50
VIIP  6 797 11
Skin laceration (untreated) 7 715 50
Dental Abscess (untreated) 8 619 100
Dental Abscess  9 473 50
Nephrolithiasis  10 293 100
Lower extremity stress fracture 
(untreated) 11 284 50
Sepsis  12 255 100
Dental: Exposed pulp (untreated) 13 233 100
Neck Injury (untreated) 14 192 50


































Medical condition  Number in trial  Occurrence rate per 100k trials  Probability of LOCL 
Sepsis  1 135 50
Traumatic hypovolemic shock 2 101 100
Stroke (CVA) 3 58 50
Medication overdose/adverse 
reaction  4 51 50
Sudden cardiac arrest 5 41 100
Head injury  6 35 50
Decompression sickness 7 33 3
Otitis media (untreated) 8 29 1
Smoke inhalation/toxic exposure  9 29 6
Appendicitis  10 26 50
Sepsis (untreated) 11 18 100
Chest injury/pneumothorax  12 24 50
Chest injury/pneumothorax 
(untreated) 13 10 100
Abdominal injury  14 6 67
































Medical condition  Number in trial  Occurrence rate per 100k trials  Probability of EVAC 
VIIP 1 1050 11
Herpes Zoster reactivation 
(Shingles) (untreated) 2 128 100
Dental Abscess  3 51 50
Nephrolithiasis  4 38 100
Decompression sickness 5 27 5
Sepsis  6 22 100
Smoke Inhalation /Toxic exposure 7 17 29
Head injury  8 13 100
Wrist fracture  9 11 100
Stroke (CVA) 10 9 100
Hip/proximal femur fracture  11 9 100
Urinary retention  12 8 1
Back injury  13 7 2
Acute arthritis  14 4 19























Medical condition  Number in trial  Occurrence rate per 100k trials  Probability of LOCL 
Decompression sickness 1 16 3
Sepsis  2 8 50
Head injury 3 7 50
Stroke (CVA) 4 7 50
Chest injury/pneumothorax 5 2 50
Medication overdose/adverse 
reaction 6 2 50
Traumatic hypovolemic shock 7 2 100
Appendicitis  8 1 50
Radiation Syndrome (untreated) 9 1 100

































Medical condition  Number in trial  Occurrence rate per 100k trials  Probability of EVAC 
Skin laceration (untreated) 1 3147 50
Herpes zoster reactivation 
(Shingles) (untreated) 2 1221 100
Dental abscess (untreated) 3 1116 100
VIIP 4 1028 11
Lower extremity stress fracture 
(untreated) 5 688 50
Otitis media (untreated) 6 471 50
Gastroenteritis (untreated) 7 378 50
Urinary tract infection (untreated) 8 361 50
Decompression sickness 9 286 5
Nephrolithiasis  10 278 100
Sinusitis (untreated) 11 227 50
Sepsis 12 197 100
Dental: exposed pulp (untreated) 13 118 100
Wrist fracture (untreated) 14 106 100

































Medical condition  Number in trial  Occurrence rate per 100k trials  Probability of LOCL 
Decompression sickness 1 135 3
Sepsis 2 91 50
Traumatic hypovolemic shock 3 51 100
Medication overdose/adverse 
reaction  4 49 50
Sudden cardiac arrest 5 32 100
Stroke (CVA) 6 30 50
Head injury 7 24 50
Smoke inhalation/toxic exposure  8 21 6
Appendicitis  9 21 50
Chest injury/pneumothorax 10 18 50
Decompression sickness (untreated) 11 12 50
Sepsis (untreated) 12 10 100
Otitis media (untreated) 13 8 1
Abdominal injury  14 5 67
Head injury (untreated) 15 4 100
Lunar Outpost LOCL Drivers
Worst case, exhaustible ISS resources
